Lineage Cell Therapeutics (LCTX) Non Operating Income (2010 - 2026)
Lineage Cell Therapeutics' (LCTX) quarterly Non Operating Income came in at $405000.0 in Q1 2026, down 82.85% year-on-year from $2.4 million in Q1 2025, and down 81.25% quarter-over-quarter from $2.2 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Non Operating Income (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Non Operating Income history runs 17 years deep, the most recent figure standing at $405000.0 for Q1 2026.
- On a quarterly basis, Non Operating Income fell 82.85% year-over-year to $405000.0 in Q1 2026; TTM through Mar 2026 was -$22.9 million, a 551.53% decrease from a year earlier, with the FY2025 full-year figure at -$32.0 million, down 1205.94% from the prior year.
- Non Operating Income fell to $405000.0 in Q1 2026 per LCTX's latest filing, from $2.2 million in the prior quarter.
- Across five years, Non Operating Income topped out at $2.4 million in Q1 2025 and bottomed at -$26.0 million in Q3 2025.
- The 5-year median for Non Operating Income is $405000.0 (2026), against an average of -$1.1 million.
- Biggest YoY gain for Non Operating Income was 2193.2% in 2025; the steepest drop was 6640.55% in 2025.
- Year by year, Non Operating Income stood at $277000.0 in 2022, then soared by 494.95% to $1.6 million in 2023, then rose by 12.86% to $1.9 million in 2024, then grew by 16.13% to $2.2 million in 2025, then tumbled by 81.25% to $405000.0 in 2026.
- Per Business Quant, the three latest LCTX Non Operating Income figures stand at $405000.0 (Q1 2026), $2.2 million (Q4 2025), and -$26.0 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Lineage Cell Therapeutics | 251.15 Mn | 188.44 Mn | 1.73 Mn | 405,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 405,000.00 |
| Dec 31, 2025 | 2.16 Mn |
| Sep 30, 2025 | -25.97 Mn |
| Jun 30, 2025 | 454,000.00 |
| Mar 31, 2025 | 2.36 Mn |
| Dec 31, 2024 | 1.86 Mn |
| Sep 30, 2024 | 397,000.00 |
| Jun 30, 2024 | 463,000.00 |
| Mar 31, 2024 | 103,000.00 |
| Dec 31, 2023 | 1.65 Mn |
| Sep 30, 2023 | 433,000.00 |
| Jun 30, 2023 | -179,000.00 |
| Mar 31, 2023 | 410,000.00 |
| Dec 31, 2022 | 277,000.00 |
| Sep 30, 2022 | -324,000.00 |
| Jun 30, 2022 | -2.55 Mn |
| Mar 31, 2022 | -697,000.00 |
| Dec 31, 2021 | 229,000.00 |
| Sep 30, 2021 | -2.00 Mn |
| Jun 30, 2021 | 2.12 Mn |